Cipla USFDA EIR: InvaGen Pharmaceuticals Facility Inspection Closed by US Regulator
- August 4, 2026
- Posted by: Ankit Jaiswal
- Category: News
Cipla USFDA EIR issued for InvaGen Pharmaceuticals’ Hauppauge, New York facility, confirming inspection closure. Stock at Rs 1,460, down 0.61%.
The Cipla USFDA EIR was issued to InvaGen Pharmaceuticals, Inc., a wholly-owned subsidiary of Cipla, with the US regulator confirming receipt of the Establishment Inspection Report indicating closure of the inspection for its manufacturing facility in the United States.
Click Here – Get Free Investment Predictions
The facility covered by the Cipla USFDA EIR is located in Hauppauge, Long Island, New York, USA. An EIR closure is generally viewed as a positive regulatory outcome, signalling that the USFDA has completed its review of the inspection findings without further open observations requiring resolution, a milestone that typically follows a period of remediation work at the site.
| Detail | Value |
|---|---|
| Subsidiary involved | InvaGen Pharmaceuticals, Inc. |
| Facility location | Hauppauge, Long Island, New York, USA |
| Regulatory outcome | EIR issued, inspection closed |
| Cipla stock move | Down 0.61% to Rs 1,460 |
What the Cipla USFDA EIR Means
An Establishment Inspection Report, or EIR, is issued by the USFDA once it completes its evaluation of a facility inspection. Receiving the Cipla USFDA EIR for the InvaGen facility indicates the regulator considers the site’s corrective actions and compliance status satisfactory, removing a source of regulatory overhang that can otherwise weigh on a facility’s ability to receive new product approvals or file fresh Abbreviated New Drug Applications tied to that site. Facilities operating under an open inspection classification can face delays in product approvals until an EIR or similar clearance is issued, making today’s update a meaningful compliance milestone.
Track Cipla fundamentals and regulatory updates on the Univest Screener
Cipla Stock: Muted Reaction to the USFDA EIR
Despite the Cipla USFDA EIR being a generally favourable regulatory development, the stock was quoting lower at Rs 1,460, down Rs 9 or 0.61%, with an intraday range of Rs 1,455.70 to Rs 1,476.45. Trading volumes were also notably light at 2,972 shares, compared with the five-day average of 117,205 shares, a decrease of 97.46%. Such a light-volume session suggests the broader market may have already priced in the facility’s eventual clearance, or that traders were largely on the sidelines ahead of other pending catalysts for the stock.
Download the Univest iOS App or Univest Android App to track Cipla live price and USFDA regulatory updates.
Why USFDA Facility Clearances Matter for Cipla
Cipla and its US-facing subsidiaries such as InvaGen Pharmaceuticals rely heavily on maintaining clean USFDA compliance status to keep existing product approvals active and to support the pipeline of new generic and specialty drug filings for the US market. A clean EIR outcome, like the one behind this Cipla USFDA EIR update, reduces near-term regulatory risk for the company’s US business, one of its largest export markets, and can also support the timely launch of pending product filings tied to this specific facility.
Conclusion
The Cipla USFDA EIR for its InvaGen Pharmaceuticals facility in Hauppauge, New York, reflects a favourable regulatory outcome, even as the stock traded lower on the day. Investors should track further USFDA filings and product approvals tied to this facility in the coming quarters, and consult a SEBI-registered advisor before making investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Cipla USFDA EIR about?
Ans. The Cipla USFDA EIR was issued to InvaGen Pharmaceuticals, a wholly-owned Cipla subsidiary, confirming closure of a USFDA inspection at its Hauppauge, New York facility.
What does an EIR from the USFDA signify?
Ans. An Establishment Inspection Report (EIR) signifies that the USFDA has completed its review of a facility inspection, and closure generally indicates satisfactory compliance status.
Where is the facility covered by the Cipla USFDA EIR located?
Ans. The facility is located in Hauppauge, Long Island, New York, USA, and is operated by InvaGen Pharmaceuticals, Inc.
How did Cipla shares react to the USFDA EIR news?
Ans. Cipla shares were down 0.61% at Rs 1,460 despite the favourable Cipla USFDA EIR news, with trading volumes well below the five-day average.
Why do USFDA facility clearances matter for Cipla?
Ans. USFDA facility clearances like this Cipla USFDA EIR help maintain existing product approvals and support new drug filings for Cipla’s US business, one of its key export markets.
Where can I track Cipla share price live?
Ans. You can track Cipla share price, fundamentals and regulatory updates live on the Univest Screener and the Univest app.
Should I buy Cipla shares after this USFDA news?
Ans. Whether to buy Cipla shares depends on your risk appetite, investment horizon and portfolio context. Consult a SEBI-registered advisor before making investment decisions.
What products does InvaGen Pharmaceuticals manufacture?
Ans. InvaGen Pharmaceuticals, the Cipla subsidiary covered by this Cipla USFDA EIR, manufactures generic pharmaceutical products for the US market from its US-based manufacturing facilities.
